Depiction of Being patient: what delays access to new drugs in Europe?

Being patient: what delays access to new drugs in Europe?



On average, the first citizen to access a new drug in Belgium will wait 13 months longer for it than someone prescribed the same drug in Germany or the UK, despite an EU-wide licensing process. This suggests that country-specific drug regulation—the ‘fourth hurdle’ faced by drug manufacturers—may go a long way to explaining launch delay across Europe.


Related

Articles
12 minute read
Depiction of Stepping on the gas: European emergency measures to deal with high energy prices

Stepping on the gas: European emergency measures to deal with high energy prices

High gas and electricity prices across Europe have raised urgent concerns and started a debate about possible ways to mitigate the impacts on consumers. Countries have adopted a variety of national measures, which can be broadly classified under four categories: retail market interventions, wholesale market interventions, security of supply… Read More

Articles
9 minute read
Depiction of Who doesn’t invest and why? A behavioural data science perspective

Who doesn’t invest and why? A behavioural data science perspective

As we adjust to a high inflation environment, those who are fortunate enough to have savings are seeing their purchasing power erode by up to 10% per year. In the UK, one way to mitigate the effects of inflation is through investing in Stocks and Shares ISAs. But why… Read More

Back to top